Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Stopped early · Phase 2
Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may be an effective treatment for multiple myeloma. PURPOSE: This phase II trial is studying the side effects of giving lenalidomide together with rituximab and to see how well it works in treating patients with recurrent or refractory multiple myeloma.
Key facts
- Study ID
- NCT00567229
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 3
- Starts
- 2007-11-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2015-11-20
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.